Basic Informations

C.V

B.Sc., MPharm., Ph.D

Department of Clinical Pharmacy and Pharmacy Practice

Faculty of Pharmacy

Beni Suef University

                                    E-mail: amira.ahmed@pharm.bsu.edu.eg

 

1. PERSONAL DATA

Name: Amira S Ahmed

Nationality: Egyptian

 

2. ACADEMIC/PROFESSIONAL PARTICULARS

 

 

 

 

 

 

3. CAREER DETAILS

(a) Academic Positions Held

1. Working as a demonstrator in department of Pharmaceutics, Faculty of Pharmacy, Beni- suef University, Egypt from 2003-2006.

2. Working as an assistant lecturer in department of Pharmaceutics, Faculty of Pharmacy, Beni-suef University, Egypt from 2007 –2008.

3. Working in several Pharmacies as a Community Pharmacist in Egypt 2002-2007.

4. Working as a demonstrator in department of Pharmacy & Pharmaceutical Sciences, School of Applied Sciences, Huddersfield University, Huddersfield, United Kingdom from 29/9/ 2008 to 1/12/2011

4. Supervising Final year project of Pharmaceutical management BSc student, school of Pharmacy, Huddersfield University, Huddersfield, United Kingdom UK 2009/2010.

5. Working as an assistant professor of Clinical Pharmacy in Faculty of Pharmacy, Beni- Suef University, Egypt, from Feb 2012 to Aug 2014.

 

6. Preparing and teaching Community Pharmacy, Clinical Pharmacy 1, Clinical Pharmacy 2, Hospital Pharmacy, Clinical Pharmacokinetics and drug information, gastroenterology, and treatment of paediatric diseases courses for Undergraduates and Clinical Pharmacokinetics, Pharmacy Practice and Pharmaceutical Care courses for postgraduates in Faculty of Pharmacy, Beni Suef University, Beni Suef.

7. Preparing the community Pharmacy course as an e-course to be soon uploaded and used on the Egyptian National e-learning courses website http://cms.nelc.edu.eg/

8. Oral examiner for undergraduate students at faculty of pharmacy Beni-Suef University

9. Working as visiting lecturer to prepare and teach Clinical Pharmacy 1 and Clinical Pharmacy 2, Clinical Pharmacokinetics and Community Pharmacy course syllabuses in Faculty of Pharmacy, Nahda University, Beni Suef, Egypt 2011-2012, and 2012-2013.

10. Creating and supervising training for clinical pharmacy undergraduate, Faculty of Pharmacy, Beni Suef University, Beni Suef, in the teaching hospital of Faculty of Medicine, Beni Suef University for two months in Surgery, Gynaecology, pulmonary, cardiology, ICU, nephrology, infectious diseases, oncology, Gastroenterology and paediatric words, summer of academic years 2011-2012, 2012-2013.

 

4. TEACHING

• Pharmacy practice (the course discusses the major concepts of pharmaceutical care for common illnesses, and therapeutic skills in its management).

• Clinical pharmacy (the course discusses the pathophysiology and therapeutics of major disease states and concentrates on designing a complete therapeutic plan for provided case

• Drug information (the course reviews different drug information resources and define legal and ethical issues relevant to drug information.

• Clinical pharmacokinetics (the course discusses the principles of pharmacokinetics of individual drugs with emphasis on clinical application based on patient clinical presentations

• Hospital pharmacy (the course discusses major concepts of hospital pharmacy and the role of hospital pharmacist.

• Gastroenterology (the course provides fundamental understanding of gastrointestinal tract & pathophysiology of different diseases, and the therapeutic skills in their management

• Paediatrics (the course discusses major concepts of pharmaceutical care of the major Pediatrics disease states, their pathophysiology, and the therapeutic skills in their management

• Endocrinology (the course discusses major concepts of pathophysiology and Pharmacotherapy of Endocrine/Reproduction

• Neurological diseases (the course discusses major concepts of pathophysiology and Pharmacotherapy of neurological diseases)

 

5. Research Experience:

 

MSc. Pharmaceutics: The research topic is (Pharmaceutical study on prolonged release solid dosage forms of certain statins)

Summary of the research topic: preparation of a controlled release solid dosage forms of simvastatin (tablets and capsules) that fulfil the requirements for extended release medications using different hydrophilic and hydrophobic polymers, evaluation of the release rate profiles, physical and chemical stability and bioavailability determination. It could be concluded from this research study that; simvastatin could be formulated into different solid dosage forms that show physical and chemical stability and offer optimum drug release required for controlled release formulations

 

 

 

PhD Clinical Pharmacy: The research topic is (Urinary Pharmacokinetic Methodology to Determine the Relative Lung Bioavailability of Inhaled Beclometasone)

Summary of the research topic: Development and application of a urinary pharmacokinetic methodology to assay urine beclometasone concentrations and determine the relative lung and systemic bioavailability together with in-vitro studies to determine the aerodynamic characteristics when using different inhalation methods. The research study highlights the extension of the urinary pharmacokinetic method to inhaled beclometasonedipropionate and demonstrates its usefulness to compare different inhalation methods and different formulations. It also provides further evidence of in-vitro in-vivo correlations between the urinary methodology and the aerodynamic characteristics of the emitted dose

 

6. PUBLICATIONS

• Ahmed A, Harding L, and Chrystyn H. Urinary Pharmacokinetic Method to Identify the Relative Bioavailability of Beclometasone Dipropionate (BDP) to the Lung and Body following Inhalation, Presented as a Poster to the European Respiratory Society (ERS) Annual Congress, 2010, Barcelona, Spain.

• Ahmed A, Harding L, and Chrystyn H. Urinary Pharmacokinetic Method to Identify the Relative Lung And Systemic Bioavailability of Inhaled Beclometasone Dipropionate (BDP) Using BDP, Beclometasone-17-Monopropionate (BMP) and Beclometasone (BOH) Excretion. Presented at the 18th Congress of the International Society of Aerosols in Medicine, 2011, Rotterdam, the Netherlands.

• Ahmed A, Harding L, and Chrystyn H. Urinary pharmacokinetic methodology to determine the Relative lung bioavailability of inhaled beclometasone, Br J Clin Pharmacol. Sep 2012; 74(3): 456–464. Published online Feb 2, 2012.

• Ahmed A, Harding L, and Chrystyn H. Beclometasone relative lung and systemic bioavailability from two different HFA-BDP formulations with different spacers (Submitted for publication in Br J Clin Pharmacol).

• Ali, A. A., Abdelrahim, M. E., Elmoslamy, N. A., Said, A. S. & Meabed, M. H. (2014) Comparison Between Nitazoxanide and Metronidazole in the Treatment of Protozoal Diarrhea in Children. Med-Science, 3 (2), 1162-73. doi:10.5455/medscience.2013.02.8117

• Hassanein, A. H. A., Abdelrahim, M. A., Said, A. S., Hussein, R. R. & Abuseif, M. (2014) The Incidence of Upper Gastrointestinal Complications of Non-Steroidal Anti-Inflammatory Drugs in Elderly Patients. Med-Science, 3 (1), 1032-45. doi:10.5455/medscience.2013.02.8105

• Kamal, Y. M., Abdelrahim, M.E., Said, A.S., Botrous, O.E., Ahmed, A. & Meabed, M.H. The efficacy of elemental Zinc on acute diarrhea in Egyptian infants and children Med-Science, Online First: 18 Jul, 2014. doi:10.5455/medscience.2014.03.8176

• Said, A.S., Abdelrahman, M.A and Abo seif, M. A. Sequential therapy versus standard triple Therapy for helicobacter pylori eradication, Presented as a Poster to the Emirates Gastroenterology and Hepatology conference (EGHC) Annual Congress, 2014, Dubai, Unites Arab of Emirates (UAE).

• Menshawe, S. F. E., Ahmed, A. S., Aty, L. N. A. & Seif, M. A. A. (2014) Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients. Med-Science, 3 (4), 1655-74. doi:10.5455/medscience.2014.03.8173

• Ahmed, A. S., Wahsh, E. A. & Ahmed, E. E. G. Comparative Study of Oral Daily Amoxicillin, Long Acting Intramuscular Penicillin, and Tonsillectomy in Prevention of Recurrent Pharyngitis. Med-Science, Online First: 07 Jan, 2015. doi:10.5455/medscience.2015.04.8224

• Hassan, A., Rabea, H., Roshdy, R., Salah Eldin, R., Abdel Rahman, M., Said, A., Salem, H., Abdelrahim, M. In-vitro characterization of the aerosolized dose during non-invasive ventilation" (accepted for publication in in Journal of Pharmacy and Pharmacology.

 

 

 

 

 

.

 

 

 

 

 

 

 

 

 

 

 

Master Title

invitro and invivo study of simvastatin sustained release dosage forms

Master Abstract

In vitro and in vivo pharmacokinetic study of sustained release simvastatin tablets and capsules Summary of the research topic: Preparation of a controlled release solid dosage forms of simvastatin (tablets and capsules) that fulfil the requirements for extended release medications using different hydrophilic and hydrophobic polymers, evaluation of the release rate profiles, physical and chemical stability and bioavailability determination. It could be concluded from this research study that; simvastatin could be formulated into different solid dosage forms that show physical and chemical stability and offer optimum drug release required for controlled release formulations

PHD Title

urinary pharmacokinetic method to determine the relative lung bioavailability of inhaled beclometasone

PHD Abstract

Urinary Pharmacokinetic Methodology To Determine The Relative Lung Bioavailability Of Inhaled Corticosteroids Urinary pharmacokinetic methods have been introduced to identify the relative lung and systemic availability of inhaled drugs but have not been extended to corticosteroids. The main aims were to validate the urinary pharmacokinetic methodology when applied to inhaled beclometasone dipropionate (BDP), demonstrate the usefulness of the method and compare its indices to the in-vitro characteristics of the emitted dose. A simple and sensitive LC-MS method for quantifying BDP and its metabolites in methanol (for in-vitro studies) and urine samples was identified and validated in accordance with the FDA and ICH guidelines. The accuracy, precision, and recovery of the method were within acceptable limits (±15%). Twelve healthy volunteers completed the in-vivo urinary pharmacokinetic validation of the methodology to determine the relative lung bioavailability of inhaled beclometasone following inhalation. Twelve healthy volunteers received randomised doses, separated by >7 days, of 2000µg BDP solution with (OralC) and without (Oral) 5g oral charcoal, ten 100µg inhalations from a Qvar® Easi breathe metered dose inhaler (pMDI) with (QvarC) and without (Qvar) oral charcoal and eight 250µg inhalations from a Clenil® pMDI (Clenil). Subjects provided urine samples at 0, 0.5, 1, 2, 3, 5, 8, 12, and 24 hours post study dose. Urinary concentrations of BDP and its metabolites, 17-beclometasone monopropionate (BMP) and beclometasone (BOH) were measured. No BDP, BMP, or BOH was detected in any samples post OralC dosing. Post oral dosing, no BDP was detected in any of the urine samples and no BMP or BOH was excreted in the first 30 minutes. Significantly more (p<0.001) BDP, BMP and BOH was excreted in the first 30 minutes and cumulative 24 urinary excretions post Qvar and Clenil compared to Oral. Using 30 minute urinary excretion the mean ratio (90% confidence interval) for Qvar compared to Clenil was 231.4 (209.6, 255.7). The results confirm that the relative lung and systemic bioavailability can be identified from urinary excretion of BDP and its metabolites over the first 30 minutes and 24 hours respectively. The 2-fold difference between Qvar and Clenil is consistent with related clinical and pharmacokinetic studies. The low inter and intra-subject variability of the study confirms the reproducibility of this method. When compared to the in-vitro aerodynamics characteristics of the emitted dose, using standard compendial methods, the in-vivo indices showed a relationship to the fine particle dose (FPD) and the emitted dose (ED), respectively. The application of this urinary pharmacokinetic method was demonstrated in further studies to compare the effect of different spacers and different washing methods on the in-vivo drug delivery post inhalation from Clenil and Qvar inhalers in healthy volunteers. In addition, the in-vitro aerodynamic particle size distribution of the same inhalation methods has been investigated using the Andersen Cascade Impactor according to the standard compendial methodology. Urinary excretion, using 24 hour excretion, revealed that relative bioavailability to the body was reduced with spacers for both inhalers. There was no increase in the relative lung bioavailability when Qvar was used with spacers. When Clenil was attached to a spacer (either AeroChamber or Volumatic) the relative lung bioavailability was significantly greater only if the spacers were not rinsed after washing with detergents. Consistent with the above study there were correlations between the in-vivo urinary indices and the in-vitro characteristics of the emitted dose. The thesis highlights the extension of the urinary pharmacokinetic method to inhaled beclometasone dipropionate and provides further evidence of in-vitro in-vivo correlations between the urinary methodology and the aerodynamic characteristics of the emitted dose. Keys words: beclometasone dipropionate, metabolites, urinary excretion, metered dose inhalers, spacers, relative lung bioavailability, and in-vitro dose emission.